Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing enzymatic therapies for tissue repair and wound care. The company operates primarily in the biotechnology and advanced therapeutics industries, with a concentration on severe burn treatment, chronic wound management, and biologics-based debridement technologies. Its core commercial product is NexoBrid, a bromelain-based biologic therapy designed for eschar removal in severe thermal burns. The company is also advancing EscharEx for chronic wounds and MW005 for non-invasive treatment applications in dermatology and aesthetic medicine.
The company generates revenue through product sales, licensing agreements, government-supported development programs, and strategic collaborations. MediWound’s customer base includes hospitals, burn centers, military and emergency preparedness organizations, and healthcare systems in multiple international markets. A key strategic differentiator is its proprietary bromelain-derived enzymatic platform, which enables selective tissue debridement while potentially reducing surgical intervention requirements. Founded in Israel in 2000, MediWound evolved from an early-stage biotechnology developer into a publicly traded company listed on Nasdaq under the ticker MDWD, with expanded regulatory approvals and international commercialization partnerships over time.
Business Operations
MediWound’s operations are centered around its enzymatic debridement platform and related biologic therapeutics. Its principal business activities include commercialization of NexoBrid, clinical development of EscharEx, and advancement of additional pipeline assets using bromelain-based technologies. Revenue is primarily derived from commercial sales, milestone payments, BARDA-related development funding, and collaboration agreements. The company operates through integrated research, clinical development, regulatory affairs, manufacturing oversight, and commercialization functions.
Internationally, MediWound has commercial reach across parts of Europe, Israel, and additional global markets through distribution and licensing partners. The company maintains strategic collaborations with organizations including Vericel Corporation for North American commercialization activities and has previously worked with governmental agencies such as the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support burn preparedness initiatives. MediWound controls proprietary enzymatic extraction and formulation technologies related to bromelain-derived therapeutics and relies on specialized biologics manufacturing capabilities to support clinical and commercial supply.
Strategic Position & Investments
MediWound’s strategic direction emphasizes expansion of its enzymatic biologics platform into broader wound care and tissue repair applications. A major growth initiative involves continued adoption and geographic expansion of NexoBrid, particularly following regulatory approvals in additional jurisdictions, including the United States. The company is also investing in late-stage development of EscharEx, which targets chronic and hard-to-heal wounds, a significantly larger commercial market than acute burn care. Clinical development efforts are intended to diversify revenue sources beyond severe burns and strengthen the company’s position in advanced wound management.
The company has also pursued strategic funding and commercialization relationships to reduce development risk and expand market access. BARDA support has provided non-dilutive funding for burn-related programs and emergency preparedness initiatives. MediWound’s partnership with Vericel Corporation supports commercialization infrastructure in North America, while additional regional distributors support international market penetration. The company’s broader investment focus remains concentrated on biologics, enzymatic therapeutics, and regenerative wound-care technologies rather than large-scale acquisition activity. Public disclosures indicate continued investment in research and development capabilities and clinical pipeline advancement.
Geographic Footprint
MediWound is headquartered in Yavne, Israel, and operates internationally through commercial partnerships, distributors, and clinical development activities. The company’s products and clinical programs have presence across Europe, North America, and selected additional international markets. Regulatory approvals and commercialization efforts have expanded over time through partnerships with regional healthcare companies and distributors.
The company maintains strategic operational influence in the United States through regulatory engagement, BARDA-supported initiatives, and commercialization agreements. European markets represent an important commercial base for NexoBrid, while Israel remains central to research, development, and corporate operations. MediWound’s global footprint is relatively specialized compared with larger pharmaceutical companies but is strategically aligned with burn-care centers, military preparedness networks, and advanced wound-care institutions internationally.
Leadership & Governance
MediWound was founded by biotechnology entrepreneurs and scientists associated with development of bromelain-based therapeutic technologies in Israel. The company operates under a governance structure typical of publicly traded biotechnology firms, with executive leadership focused on clinical development, regulatory expansion, commercialization partnerships, and shareholder value creation. Corporate strategy has consistently emphasized innovation in enzymatic therapeutics and expansion into broader wound-care applications.
Key executives and leadership include:
- Ofer Gonen – Chief Executive Officer
- Sharon Malka – Chief Financial Officer
- Dr. Amir Kaplan – Chief Medical Officer
- Roni Kraus – Vice President, Human Resources
- Gilad Glick – Chairman of the Board
Leadership communications and public filings indicate a strategic focus on expanding the commercial reach of NexoBrid, advancing the late-stage clinical pipeline, and strengthening MediWound’s position in biologics-based wound care through partnerships, regulatory execution, and continued research investment.